Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired (Tables)

Licenses Acquired (Tables)

6 Months Ended

Jun. 30, 2018

Research and Development Arrangement, Contract to Perform for Others

As such, for the three and six months ended June 30, 2018 and 2017, the purchase price of licenses acquired was classified as research and development-licenses acquired in the Condensed Consolidated Statements of Operations, as reflected in the table below:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
($ in thousands)	2018		2017		2018		2017
Fortress	$		$	300	$		$	300

Fortress Companies:
Checkpoint								400
Helocyte						21
Mustang				1,500		75		2,075
Cellvation						1
Caelum								219
Cyprium								100
Aevitas		1				1
Total	$	1	$	1,800	$	98	$	3,094

Schedule of Licenses Acquired Expenses [Table Text Block]

The table below provides a summary of Checkpoint’s expense related to its licenses, for the three and six months ended June 30, 2018 and 2017 by license as recorded in the Condensed Consolidated Statements of Operations:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,
($ in thousands)	2018	2017	2018	2017
Jubliant Biosys License CK-103	$	$	$	$	400
Total Licenses Acquired Expense	$	$	$	$	400

The table below provides a summary of Mustang’s expense related to its licenses, for the three and six months ended June 30, 2018 and 2017 by license as recorded in the Condensed Consolidated Statements of Operations:

	For the Three Months Ended June 30,			For the Six Months Ended June 30,
($ in thousands)	2018	2017		2018		2017
City of Hope (COH) IL-13 License	$	$		$		$	250
COH IV/ICV License							125
COH HER2 License			600				600
COH CS-1 License			600				600
COH License for PSCA			300				500
Manufacturing License					75
Total licenses acquired expense	$	$	1,500	$	75	$	2,075